Complement protein holds diagnostic, prognostic promise in lung cancer
medwireNews
medwireNews: A complement activation product known as “C4d” may have value as a diagnostic and prognostic biomarker for lung cancer, research suggests.
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Your new post is loading...
Your new post is loading...
|
Alfredo Corell's curator insight,
October 27, 2013 7:00 PM
Poor quality in the lab not only forces an organization into a reactive mode of problem solving, but it also creates a higher cost burden than a laboratory with an effective quality infrastructure experiences. Reruns performed due to quality control failures can significantly increase testing costs and cut into a lab’s bottom line. Furthermore, according to a recent study, correction of errors across all phases of laboratory testing can consume 12-35 percent of technician time.
|